About Lantheus
Lantheus is a company based in Billerica (United States) founded in 2008. The company has 808 employees as of December 31, 2024. Lantheus has completed 5 acquisitions, including Cerveau Technologies, Evergreen Theragnostics and Life Molecular Imaging. Lantheus offers products and services including PYLARIFY, AZEDRA, DEFINITY, and LUMINITY. Lantheus operates in a competitive market with competitors including Advanced Accelerator Applications, AIdoc, Olympus, SOFIE and Siemens Healthineers, among others.
- Headquarter Billerica, United States
- Employees 808 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lantheus Holdings, Inc.
-
Annual Revenue
$1.53 B (USD)18.32as on Dec 31, 2024
-
Net Profit
$312.44 M (USD)-4.35as on Dec 31, 2024
-
EBITDA
$510.49 M (USD)-7.76as on Dec 31, 2024
-
Latest Funding Round
$300 K (USD), Grant
Jun 19, 2012
- Investors
-
Employee Count
808
as on Dec 31, 2024
-
Investments & Acquisitions
Cerveau Technologies
& 4 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lantheus
Lantheus is a publicly listed company on the NASDAQ with ticker symbol LNTH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lantheus
Lantheus offers a comprehensive portfolio of products and services, including PYLARIFY, AZEDRA, DEFINITY, and LUMINITY.
Radiopharmaceutical for detecting prostate cancer in patients.
Treatment for certain neuroendocrine tumors.
Ultrasound contrast agent for cardiac imaging.
Contrast agent for ultrasound procedures.
People of Lantheus
Unlock access to complete
Unlock access to complete
Software Development Team
77 people
Leadership Team
55 people
Finance and Accounting
16 people
Product Management Team
14 people
Senior Team
10 people
Human Resources and Administration
8 people
Operations Team
8 people
Head Team
7 people
Unlock access to complete
Funding Insights of Lantheus
Investors in Lantheus
Lantheus has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Lantheus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lantheus
Lantheus has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Cerveau Technologies, Evergreen Theragnostics and Life Molecular Imaging.
Investment portfolio details for Lantheus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Radiopharmaceutical manufacturing and regulatory services are provided.
|
Locked | Locked | 2019 | Locked | |
|
Provider of biomarkers and therapeutics development services
|
Locked | Locked | 2018 | Locked | |
|
Research collaborations and global strategies are employed for product development.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Lantheus
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Lantheus
Detailed financials for Lantheus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lantheus Comparisons
Peer comparison for Lantheus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lantheus
Lantheus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, AIdoc, Olympus, SOFIE and Siemens Healthineers, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
AI-based single-screen system is provided to streamline medical imaging.
|
|
| Locked | Locked | Locked |
Manufacturer of imaging and surgical products
|
|
| Locked | Locked | Locked |
Developer of molecular imaging systems and radio-pharmaceuticals
|
|
| Locked | Locked | Locked |
AI-based medical diagnostics are developed for healthcare applications.
|
|
| Locked | Locked | Locked |
Atherosclerotic plaque is quantified by AI using coronary CT angiograms.
|
Detailed competitors of Lantheus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lantheus
Complete news archive for Lantheus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lantheus
Lantheus was founded in 2008 and raised its 1st funding round 3 years after it was founded.
Lantheus is headquartered in Billerica, United States. It is registered at Billerica, Massachusetts, United States.
As of Dec 31, 2024, the latest employee count at Lantheus is 808.
Annual revenue of Lantheus is $1.53B as on Dec 31, 2024.
Developer of diagnostic imaging agents and targeted therapeutics. The companys lead candidate is PNT2002 a small molecule PSMA-targeted 177Lu-based radioligand therapy for metastatic castration-resistant prostate cancer. It also offers software like DEFINITY, VIALMIX, PINSYNC, TechneLite, and more. It offers imaging agents that assist in the diagnosis of heart and vascular diseases with nuclear imaging, echocardiography, and magnetic resonance imaging (MRI) technologies.
Lantheus's top competitors include Advanced Accelerator Applications, AIdoc and Olympus.
Lantheus offers PYLARIFY, AZEDRA, DEFINITY, and LUMINITY.
Yes, Lantheus is publicly traded on NASDAQ under the ticker symbol LNTH.
Lantheus has made 5 acquisitions, including Cerveau Technologies, Evergreen Theragnostics, and Life Molecular Imaging.
Lantheus has 1 investor. Key investors include HHS.
The ticker symbol of Lantheus is LNTH on NASDAQ.